Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

ARTICLES https://doi.org/10.1038/s41591-021-01318-5 Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies 1,2,3,22 1,2,3,221,2,3,4 1,2,3 Delphine Planas, Timothée Bruel, Ludivine Grzelak, Florence Guivel-Benhassine, 1,2,3 1,2,35 1,2,3 Isabelle Staropoli, Françoise Porrot, Cyril Planchais, Julian Buchrieser, 1,2,3,4 1,2,3,46,7 6,78 Maaran Michael Rajah, Elodie Bishop, Mélanie Albert, Flora Donati, Matthieu Prot, 6,7 6,79 1010 Sylvie Behillil, Vincent Enouf, Marianne Maquart, Mounira Smati-Lafarge, Emmanuelle Varon, 11 1213 14,1516 Frédérique Schortgen, Layla Yahyaoui, Maria Gonzalez, Jérôme De Sèze, Hélène Péré, 16,17 188 19,209,21 David Veyer, Aymeric Sève, Etienne Simon-Lorière, Samira Fafi-Kremer, Karl Stefic, 5 186,7,23 18,23 Hugo Mouquet, Laurent Hocqueloux, Sylvie van der Werf, Thierry Prazuckand ᅒ 1,2,3,23 Olivier Schwartz Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.7 and B.1.351 variants were first identified in the United Kingdom and South Africa, respectively, and have since spread to many countries. These variants harboring diverse mutations in the gene encoding the spike protein raise important concerns about their immune evasion potential. Here, we isolated infectious B.1.1.7 and B.1.351 strains from acutely infected individuals.